Newly diagnosed glioblastoma

A review on clinical management

Research output: Contribution to journalReview article

Abstract

Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classifi cation of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumortreating fi elds will be presented. Pivotal studies defi ning our current standard of care will be highlighted, as will key ongoing trials that may infl uence our management of glioblastoma in the near future.

Original languageEnglish (US)
Pages (from-to)91-100
Number of pages10
JournalONCOLOGY (United States)
Volume33
Issue number3
StatePublished - Jan 1 2019

Fingerprint

Glioblastoma
Central Nervous System Neoplasms
Standard of Care
Cations
Radiotherapy
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{8d7bd1a204e44721868e1d177c6d758d,
title = "Newly diagnosed glioblastoma: A review on clinical management",
abstract = "Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classifi cation of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumortreating fi elds will be presented. Pivotal studies defi ning our current standard of care will be highlighted, as will key ongoing trials that may infl uence our management of glioblastoma in the near future.",
author = "Lukas, {Rimas Vincas} and Wainwright, {Derek Alan} and Erik Ladomersky and Sean Sachdev and {Sonabend Worthalter}, {Adam Mendel} and Roger Stupp",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "33",
pages = "91--100",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Newly diagnosed glioblastoma

T2 - A review on clinical management

AU - Lukas, Rimas Vincas

AU - Wainwright, Derek Alan

AU - Ladomersky, Erik

AU - Sachdev, Sean

AU - Sonabend Worthalter, Adam Mendel

AU - Stupp, Roger

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classifi cation of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumortreating fi elds will be presented. Pivotal studies defi ning our current standard of care will be highlighted, as will key ongoing trials that may infl uence our management of glioblastoma in the near future.

AB - Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classifi cation of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumortreating fi elds will be presented. Pivotal studies defi ning our current standard of care will be highlighted, as will key ongoing trials that may infl uence our management of glioblastoma in the near future.

UR - http://www.scopus.com/inward/record.url?scp=85069734002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069734002&partnerID=8YFLogxK

M3 - Review article

VL - 33

SP - 91

EP - 100

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -